Doctors warn against DIY use
Physicians and commentators are warning that unsupervised GLP‑1 use can carry risks like muscle loss, nutritional gaps and long‑term metabolic impacts, urging medical oversight (theweek.in). The coverage frames easier access via pills as not a license for casual self‑medication (theweek.in).
Glucagon-like peptide 1 drugs work by copying a gut hormone that slows stomach emptying and reduces appetite, and doctors are warning that using them without supervision can carry real risks. (nejm.org) Those risks are not limited to nausea and vomiting. A recent New England Journal of Medicine review said side effects are “mostly gastrointestinal” but can also include loss of muscle and bone mass, while the United States Food and Drug Administration label for semaglutide lists boxed and other warnings, contraindications, and dose-escalation instructions. (nejm.org) (accessdata.fda.gov) The warning is landing as semaglutide pills move further into obesity treatment. The Food and Drug Administration’s labeling for Wegovy tablets says the oral form was studied for up to 64 weeks in 204 adults with obesity or overweight plus a weight-related condition, and approved for long-term weight reduction with diet and physical activity. (accessdata.fda.gov) Doctors are focusing on what happens when appetite drops faster than eating habits improve. A joint clinical advisory published in 2026 said patients on these drugs need nutrition management to prevent nutrient deficiencies and preserve muscle and bone mass, including adequate protein intake and resistance exercise. (pmc.ncbi.nlm.nih.gov) That concern is showing up in early real-world data. A 2025 observational study found glucagon-like peptide 1 receptor agonist use in adults with type 2 diabetes was associated with nutritional deficiencies and muscle loss, and a 2026 Harvard Health summary of a review said vitamin D, iron, and B-vitamin shortfalls were among the reported problems. (pmc.ncbi.nlm.nih.gov) (health.harvard.edu) Researchers are also tracking what weight loss is made of. A randomized clinical trial published in JAMA Network Open found bone mineral density fell at the hip and spine after a low-calorie intervention followed by liraglutide, while exercise helped preserve bone at some sites. (jamanetwork.com) The drugs still have documented benefits when they are prescribed and monitored. The New England Journal of Medicine review said large randomized trials have shown glucagon-like peptide 1 receptor agonists lower blood glucose, reduce body weight, cut cardiovascular risk, and slow kidney disease progression in high-risk patients. (nejm.org) That is why physicians are drawing a line between medical use and casual self-medication. The same Food and Drug Administration materials that expand access also tie semaglutide to screening for contraindications, gradual dose increases, and ongoing follow-up rather than do-it-yourself use. (accessdata.fda.gov)
